Objective:

To comprehensively evaluate the efficacy and safety of tegileridine at different doses in patients with postoperative acute pain through a meta-analysis.

Approach:

• Literature Search: Systematic literature search across six databases to identify randomized controlled trials involving tegileridine for postoperative acute pain.
• Meta-Analysis: Meta-analyses performed using RevMan 5.4 software on data from included studies.

Key Findings:

• Tegileridine significantly reduced rSPID24 and rSPID12 compared to placebo.
• No significant difference in efficacy was observed between tegileridine and morphine at rSPID12, but tegileridine was significantly weaker than morphine at rSPID24.
• Total adverse events with tegileridine were higher than placebo but comparable to morphine.
• Incidence of nausea and vomiting with tegileridine was similar to placebo and significantly lower than morphine.
• No significant difference in respiratory depression incidence between tegileridine and morphine.

Interpretation:

Tegileridine demonstrates significant efficacy over placebo and a more favorable safety profile than morphine regarding nausea and vomiting.

Limitations:

• Limited number of studies included in the meta-analysis.
• Potential biases in the included studies as assessed by the Cochrane Risk of Bias tool.

Conclusion:

Tegileridine may serve as a viable alternative for postoperative acute pain management.

Sources:

• Systematic Review Registration